Home> Projects> AML 2: Optimizing Acute Promyelocytic Leukemia Management Using Big Data

AML 2: Optimizing Acute Promyelocytic Leukemia Management Using Big Data

Challenge: Address open issues in APL management, particularly during early stages of therapy 

Acute promyelocytic leukemia (APL) is a very rare form of leukemia and, despite advances in treatment, key clinical questions remain unanswered. The paucity of patients included in individual trials makes it difficult to definitively determine optimal management strategies based on limited data.


Status end 2019

Participation has been confirmed by several European research groups and data from at least 3,000 patients with APL are available for inclusion in the project (about 1,500 real-life patients and 1,500 patients included in clinical trials). The team intends to use these data to assess the rate of differentiation syndrome, assess the efficacy of CNS prophylaxis and maintenance therapy, determine the characteristics and outcomes of elderly APL, and to perform a long-term assessment of quality of life in APL patients.


Project Partnership


Project Leadership

This HARMONY Research Project has been developed by Prof. Francesco Lo-Coco* (1955-2019), University Tor Vergata, Italy and Marco Vignetti, GIMEMA, Italy.


Impact


Project Summary

APL is an aggressive form of leukemia but is also very rare - affecting only a small number of patients. Once regarded as the most rapidly fatal human blood cancer, treatment has advanced enormously over the decade as a result of intensive collaborative efforts in both basic and clinical research carried out at a national and international level. As a result, APL is now curable in the vast majority of patients (80–90%) using targeted agents alone or in combination with chemotherapy.

Although the treatment of APL has been revolutionized by the use of targeted and tailored agents directed towards specific oncoproteins, important open questions in disease management remain. Particular controversy exists over the best way to prevent and manage complications.

The HARMONY Big Data Platform offers the opportunity to merge APL patient populations enrolled in European trials and apply current knowledge to address specific open issues in disease management, particularly during early phases of therapy. The datasets in question already exist. Combining and collating them in the HARMONY Big Data Platform will allow comparative analyses to be carried out quickly and efficiently, yielding rapid results.

This project will analyze and compare patients receiving different treatment modalities including antileukemic therapy and preventive/supportive interventions. A particular focus will be on optimal strategies for prophylaxis and treatment of complications including differentiation syndrome, central nervous system relapses and coagulation disorders. Other open issues in APL that the HARMONY Big Data Platform will seek to decipher include the role and potential survival benefit of maintenance therapy, and optimal therapeutic choices for elderly patients. 

Ultimately, this project aims to harness the power of the HARMONY Big Data Platform to drive APL management forward. Outcomes will real-world implications for the everyday management of patients with APL in clinical practice.